GlassScriptPhysician profile
Enas Sallam
NPI 1578553434
$6,985.19
in general payments reported to CMS, 2019-2025
44 companies · $1,918 in 2025
The $1,918 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $718 · 2021: $755 · 2022: $935 · 2023: $648 · 2024: $1,346 · 2025: $1,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,813 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.87 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $829.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $817.54 | 2019-2025 | |
| Abbvie INC. | $795.53 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $458.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $430.08 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $337.21 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $296.51 | 2020-2025 | Verquvo, Gardasil 9, Enflonsia |
| Novartis Pharmaceuticals Corporation | $247.50 | 2022-2025 | |
| Exact Sciences Corporation | $227.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $220.25 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $217.07 | 2021-2025 | |
| Astellas Pharma US INC | $212.99 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $193.43 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Phathom Pharmaceuticals, INC. | $179.77 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $178.33 | 2022-2025 | Rexulti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enas Sallam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.